Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction-Reference-Cited by-同舟云学术

Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

Published:2020-01-01 Issue:1 Volume:25 Page:112-117
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Ninomoto Joi¹,Mokatrin Ahmad¹,Kinoshita Taisei¹^ORCID,Marimpietri Carol¹,Barrett Terrance D.²,Chang Betty Y.¹,Sukbuntherng Juthamas¹,James Danelle F.¹,Crowther Mark³

Affiliation:

1. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

2. Janssen Research & Development LLC, San Diego, CA, USA

3. Department of Medicine, McMaster University, Hamilton, Canada

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2020.1730080

Reference26 articles.

1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2. IMBRUVICA® (ibrutinib) capsules, for oral use. IMBRUVICA® (ibrutinib) tablets, for oral use [prescribing information]. Sunnyvale (CA): Pharmacyclics LLC; November 2019.

3. European Medicines Agency. Imbruvica: EPAR – product information. 2018. [cited 6 Feb 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf

4. Tec regulates platelet activation by GPVI in the absence of Btk

5. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection;Frontiers in Immunology;2023-12-21

2. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology;American Journal of Physiology-Cell Physiology;2022-10-01

3. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study;BMC Cancer;2022-06-13

4. Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches;International Journal of Molecular Sciences;2022-03-18

5. Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19;International Journal of Molecular Sciences;2021-10-16